PRODUCTION & OPERATIONS
AstraZeneca had a 2023 revenue of US $ 45.8bn
Inside an AstraZeneca laboratory of cancer and autoimmune diseases and has operations in China and the US .
Besides this , AstraZeneca will continue to utilise Celonis in its internal financial controls and harness Celonis ’ Process Mining capabilities .
“ While this will continue over the next 12 months , we ’ ll also be launching a new programme to do Process Mining across other business processes , beyond financial controls ,” explains Joshi . “ At AstraZeneca we ’ re excited about Celonis ’ new AI capabilities which form the heart of the Celonis Process Intelligence Graph . We are piloting AI to augment several controls
in the background . Generative AI has the potential to transform the pharmaceutical industry and we want to capitalise on its potential .”
At the end of 2023 , AstraZeneca announced a US $ 247m partnership with startup Absci , which is focused on developing generative AI ( Gen AI ) antibody discovery technology . Together , the two companies will learn more about the potential of Gen AI as they work to clear the world of cancer .
Despite already having achieved a lot in such a short space of time , Joshi feels that the company has only just scratched the surface .
manufacturingdigital . com 89